Multiple Myeloma

Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma

Treatment with the B-cell maturation antigen‚ąítargeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene ciloleucel (ide-cel) showed encouraging efficacy in patients with heavily pretreated relapsed...
WIB_icon

Lenalidomide and Dexamethasone for Older Patients With Multiple Myeloma: Less Is More

According to a study published in Blood, older patients with multiple myeloma (MM) who are taking continuous lenalidomide-dexamethasone (Rd) may be able to switch...

How Can the Myeloma Community Reduce Disparities in Care?

In our March 2021 issue, we reported on findings from a review article examining disparities in outcomes among patients with multiple myeloma (MM), in...

Idecabtagene Vicleucel Approved for Relapsed or Refractory Multiple Myeloma

The FDA has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for the treatment of...

European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma

Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...

FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma

Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...

Does Elotuzumab Improve PFS in High-Risk Myeloma?

The addition of the anti-SLAMF7 antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and maintenance did not improve outcomes for patients with previously...
WIB_icon

Ixazomib Combination Improves PFS Versus Placebo in Patients With Transplant-Ineligible Myeloma

When researchers added ixazomib to continuous lenalidomide-dexamethasone (Rd) in patients with newly diagnosed, transplant-ineligible multiple myeloma (MM), they observed that the treatment regimen was...

Daratumumab and Hyaluronidase-fihj Approved for Light Chain Amyloidosis

The combination of daratumumab and hyaluronidase-fihj and bortezomib, cyclophosphamide, and dexamethasone (D-VCd) was granted accelerated approval for the treatment of adults with newly diagnosed...

Charting the Myeloma Immunotherapy Landscape

A bevy of forthcoming immunotherapies for multiple myeloma over the next few years raises hopes, as well as questions about combinations, sequencing, and potential...
Advertisement

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title